164 related articles for article (PubMed ID: 27368955)
41. Retinal pigment epithelium folds as a diagnostic finding of Vogt-Koyanagi-Harada disease.
Kato Y; Yamamoto Y; Tabuchi H; Fukushima A
Jpn J Ophthalmol; 2013 Jan; 57(1):90-4. PubMed ID: 23149670
[TBL] [Abstract][Full Text] [Related]
42. Tomographic features of serous retinal detachment with multilobular dye pooling in acute Vogt-Koyanagi-Harada disease.
Yamaguchi Y; Otani T; Kishi S
Am J Ophthalmol; 2007 Aug; 144(2):260-5. PubMed ID: 17533104
[TBL] [Abstract][Full Text] [Related]
43. Autofluorescence findings in Vogt-Koyanagi-Harada disease.
Ayata A; Dogru S; Senol MG; Unal M; Ersanli D; Bilge AH
Eur J Ophthalmol; 2009; 19(6):1094-7. PubMed ID: 19882556
[TBL] [Abstract][Full Text] [Related]
44. Vogt-Koyanagi-Harada syndrome in a 4-year-old child.
Gruich MJ; Evans OB; Storey JM; Bradley ST; Chen CJ
Pediatr Neurol; 1995 Jul; 13(1):50-1. PubMed ID: 7575849
[TBL] [Abstract][Full Text] [Related]
45. Tomographic features of serous retinal detachment in Vogt-Koyanagi-Harada syndrome.
Maruyama Y; Kishi S
Ophthalmic Surg Lasers Imaging; 2004; 35(3):239-42. PubMed ID: 15185793
[TBL] [Abstract][Full Text] [Related]
46. The outcomes of indocyanine green angiography monitored immunotherapy in Vogt-Koyanagi-Harada disease.
Chee SP; Jap A
Br J Ophthalmol; 2013 Feb; 97(2):130-3. PubMed ID: 23212203
[TBL] [Abstract][Full Text] [Related]
47. Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.
Arevalo JF; Lasave AF; Gupta V; Kozak I; Al Harbi MB; Al Rushood AA; Al Dhibi HA
Ocul Immunol Inflamm; 2016 Oct; 24(5):521-9. PubMed ID: 26399962
[TBL] [Abstract][Full Text] [Related]
48. Choroidal thickness in eyes with posterior recurrence of Vogt-Koyanagi-Harada disease after high-dose steroid therapy.
Hashizume K; Imamura Y; Fujiwara T; Machida S; Ishida M; Kurosaka D
Acta Ophthalmol; 2014 Sep; 92(6):e490-1. PubMed ID: 24588838
[No Abstract] [Full Text] [Related]
49. Ocular brucellosis vs Vogt-Koyanagi-Harada syndrome.
Goldstein DA; Tessler HH
Arch Ophthalmol; 2006 Apr; 124(4):608-9; author reply 609. PubMed ID: 16606901
[No Abstract] [Full Text] [Related]
50. Correlation between sunset glow fundus and initial dosage of corticosteroid in patients with Vogt-Koyanagi-Harada disease.
Guo YL; Du Y; He JF
Am J Ophthalmol; 2009 May; 147(5):946; author reply 946-7. PubMed ID: 19376333
[No Abstract] [Full Text] [Related]
51. Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease.
Lu S; Taban M
Digit J Ophthalmol; 2016; 22(2):54-7. PubMed ID: 27582676
[TBL] [Abstract][Full Text] [Related]
52. Choroidal thickness in convalescent vogt-koyanagi-harada disease.
Takahashi H; Takase H; Ishizuka A; Miyanaga M; Kawaguchi T; Ohno-Matsui K; Mochizuki M
Retina; 2014 Apr; 34(4):775-80. PubMed ID: 23979311
[TBL] [Abstract][Full Text] [Related]
53. Teaching NeuroImages: A case of Vogt-Koyanagi-Harada disease with bilateral retinal detachment.
Al Banna M; Reeder S; Ghannam M; Robertson J; Stutz A
Neurology; 2019 Jul; 93(4):e421. PubMed ID: 31332094
[No Abstract] [Full Text] [Related]
54. Resolution of subretinal fluid with systemic corticosteroid treatment in acute Vogt-Koyanagi-Harada disease.
Nazari H; Rao NA
Br J Ophthalmol; 2012 Nov; 96(11):1410-4. PubMed ID: 22942161
[TBL] [Abstract][Full Text] [Related]
55. Acute Vogt-Koyanagi-Harada disease in enhanced spectral-domain optical coherence tomography.
Ishihara K; Hangai M; Kita M; Yoshimura N
Ophthalmology; 2009 Sep; 116(9):1799-807. PubMed ID: 19643489
[TBL] [Abstract][Full Text] [Related]
56. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
[No Abstract] [Full Text] [Related]
57. A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada disease.
Lee EK; Lee SY; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):359-68. PubMed ID: 25017008
[TBL] [Abstract][Full Text] [Related]
58. Full-field electroretinogram behavior in Vogt-Koyanagi-Harada disease: a 24-month longitudinal study in patients from acute onset evaluated with multimodal analysis.
Sakata VM; Lavezzo MM; da Silva FT; Rodriguez EEC; Morita C; Abdallah SF; Oyamada MK; Hirata CE; Yamamoto JH
Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2285-2295. PubMed ID: 31440820
[TBL] [Abstract][Full Text] [Related]
59. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome.
Agarwal M; Ganesh SK; Biswas J
Ocul Immunol Inflamm; 2006 Dec; 14(6):333-9. PubMed ID: 17162603
[TBL] [Abstract][Full Text] [Related]
60. The prognostic value of angiography in Vogt-Koyanagi-Harada disease.
Chee SP; Jap A; Cheung CM
Am J Ophthalmol; 2010 Dec; 150(6):888-93. PubMed ID: 20933219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
